Journal
Clinical Cancer Research
Publication Date
3-15-2022
Volume
28
Issue
6
First Page
1098
Last Page
1106
Document Type
Open Access Publication
DOI
10.1158/1078-0432.CCR-21-3382
Rights and Permissions
Mehnert JM, Mitchell TC, Huang AC, Aleman TS, Kim BJ, Schuchter LM, Linette GP, Karakousis GC, Mitnick S, Giles L, Carberry M, Frey N, Kossenkov A, Groisberg R, Hernandez-Aya LF, Ansstas G, Silk AW, Chandra S, Sosman JA, Gimotty PA, Mick R, Amaravadi RK. BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma. Clin Cancer Res. 2022 Mar 15;28(6):1098-1106. doi: 10.1158/1078-0432.CCR-21-3382. ©2022 The Authors; Published by the American Association for Cancer Research This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
Recommended Citation
Mehnert, Janice M; Hernandez-Aya, Leonel F; Ansstas, George; and et al., "BAMM (BRAF autophagy and MEK inhibition in melanoma): A phase I/II trial of dabrafenib, trametinib, and hydroxychloroquine in advanced BRAFV600-mutant melanoma." Clinical Cancer Research. 28, 6. 1098 - 1106. (2022).
https://digitalcommons.wustl.edu/oa_4/3112
Additional Links
Supplemental material is available for this article at publisher site.
